Process Excellence & Pharma Market | Pharma-IQ, Division of IQPC

Fail Early in Clinical Development if You Want to Succeed

Fri, 11 Jun 2010 04:00:00 GMT

If you are going to fail, it is better fail earlier. All phases of clinical research are

How Do We Ensure Best Practice in the Clinical Supply Chain?

Thu, 10 Jun 2010 04:00:00 GMT

Ensure is a tough word, but there are certain steps that can be taken to make the supply

PDCO and Industry Working on a New Relationship

Thu, 10 Jun 2010 04:00:00 GMT

Dr Irja Lutsar Professor of Medical Microbiology, University of Tartu and Member, PDCO

Embracing Pharmacovigilance with Technology

Fri, 04 Jun 2010 04:00:00 GMT

It is relatively common knowledge that the pharmaceutical industry must meet a range of

Challenges and Benefits of Patient-Based Phase I Trials

Pharma IQ — Mon, 24 May 2010 04:00:00 GMT

Pharma IQ held a Q&A session with Dr James Dow, Director of Clinical

Examining Asthma Exacerbation within Children and Disease Management

Pharma IQ — Thu, 20 May 2010 04:00:00 GMT

Dr Chad Oh, Director Respiratory & Inflammatory Diseases, MedImmune speaks to Pharma

Preparing and Submitting Robust Paediatric Investigation Plans

Pharma IQ — Thu, 20 May 2010 04:00:00 GMT

Pharma IQ held a Q&A session with Karl-Heinz Huemer, PDCO Member and Clinical

Predictive Biomarkers Provide Momentum to Cancer Treatments

Richard de Silva — Tue, 16 Mar 2010 04:00:00 GMT

Advancements continue to be made in the use of biomarkers to predict the growth of

Post Approval Surveillance and Continued Safety Monitoring

Fri, 04 Jun 2010 04:00:00 GMT

The appropriate outputs? New methodology HRT Risk Benefit model Acceptable risk

Vaccines and Pharmacovigilance: Meeting the Challenges in a Pandemic Situation

Fri, 04 Jun 2010 04:00:00 GMT

What is different in vaccine pharmacovigilance? Why is vaccine safety important?

Signal Definition and Signal Detection in Early Clinical Development

Wed, 02 Jun 2010 04:00:00 GMT

Signals: type of signals, data sources The multiple players of pharmacovigilance during

Signal Detection & Investigation: Optimising the Effective Use of a Detected Signal

Wed, 02 Jun 2010 04:00:00 GMT

What do we mean by signal Definitions Signal detection Sources Methods Signal evaluation

Preparing for a Pharmacovigilance Inspection

Wed, 02 Jun 2010 04:00:00 GMT

Inspection preparation Organisational charts CVs/job descriptions/training records

Developing Clinical Trials for Oncology

Fri, 21 May 2010 04:00:00 GMT

Denis Mir, Senior Manager of Clinical Operations in Oncology at Eisai Global Clinical

Defining the decision making process: Inhouse vs. outsource

Mon, 17 May 2010 04:00:00 GMT

Outlining key factors considered when looking to outsource. Preliminary search and

Supplier Relationship Management - A Need for the Pharmaceutical Industry

Mon, 17 May 2010 04:00:00 GMT

Need for Supplier Relationship Management in the Pharmaceutical Industry. Why SRM ? Why

Increasing the Efficiency of Clinical Trials of Antimicrobials: The Scientific Basis of Substantial Evidence of Effectiveness of Drugs

Wed, 10 Mar 2010 05:00:00 GMT

In the United States, drug sponsors must obtain approval from the US Food and Drug

Design, Conduct, and Analysis of Clinical Trials in Disease Due to Methicillin-Resistant Staphylococcus Aureus

Wed, 10 Mar 2010 05:00:00 GMT

Given the changing epidemiology of disease due to Staphylococcus aureus (SA), including

The Clinical Supply Chain

Fri, 12 Mar 2010 05:00:00 GMT

At a time when clinical trials demand increasingly complex supply chain support,

Sharing the Ride

Thu, 25 Mar 2010 04:00:00 GMT

Eli Lilly and Co. is a leader in researching and developing pharmaceutical-based

Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins

Tue, 18 May 2010 04:00:00 GMT

DRAFT GUIDANCE: This guidance provides recommendations to facilitate industry’s

Initiative to Reduce Unnecessary Radiation Exposure

Tue, 08 Jun 2010 04:00:00 GMT

Like all medical procedures, computed tomography (CT), fluoroscopy, and nuclear medicine